Member Info for Spikeyj

yay for aviva, good news i think. but how good?

i am not remotely an insurance specialist … would anyone who’s got more
detailed insight re solvency technicalities/insurance finances care to offer
an opinion quite how useful this should actually turn out to be for aviva?

just based on past form, he’s rather unlikely to say anything so clear
cut, as that would bring an end to the game here. …much more likely
imo that there will be yet another kind of can-kicking announcement,
manyana, manyana, cheque’s in post, etc, to keep the plates spinning.

as & when it does eventually end, my guess is that he will
simply stop updating & go silent, or leave longer & longer
intervals between updates. (? i don’t see why it would ever
be to his advantage to state clearly that there’s no deal?)

why bother?

https://www.thetimes.co.uk/article/prudential-rings-the-changes-with-focus-on-asia-dv9cpwst2?shareToken=f2b42c1b5ce0449f2f8d7a3906618495

citi liking it too, 14000 target.

if only these broker upgrades
ever meant anything, *sigh*.

five year graph looking rather nice these days.

lol, case adjourned, yet again, until next year. no surprise there.

soyo, b/c amit’s probably still trying to
persuade pis to hand over more cash.

just so long as he’s still spinning a story,
some folk could still be tempted. aimho.

ADME meant to be back in court *tomorrow* re KONH / barracuda.

meanwhile, randall connally & pals presumably trying to bide his time until
they can attempt some sort of P&D on the back of news from petronor. jmo.

i’ve never said i have any interest in ‘guiding’ or helping you, hubba.
it was your money & your loss - your choices are nowt to do with me.

(PS ? are you seriously under the impression that i am tom winnifrith?!)

? some of the fall today perhaps a negative read-across
re PARP class inhibitorsfrom the GSK news re zeluja?

couple of snippets re AZN & covid, for interest re broader s/p context:

https://www.bmj.com/content/379/bmj.o2592

https://www.fiercepharma.com/pharma/astrazeneca-weighs-spinning-division-covid-19-vaccine-antibodies-into-separate-company

ya know, i think hubbabub might hang on in there for
quite a long time. he rather reminds me of someone:

https://en.wikipedia.org/wiki/Hiroo_Onoda

https://www.thetimes.co.uk/article/aviva-looks-set-for-return-to-favour-fqzvxcnjd?shareToken=3f487cbe6ba7063e0e0bd5d3c0a6026e

text of the tempus ‘tip’, for what it’s worth.

i’m happy with those results.

(… which usually means that the
share price will tank 5%, sad lol.)

yay for R&D!

another three million shares dumped.

looks like earl off-loaded circa £18.5 - £19K overall, but is
still stuck in for another £11.5K. interesting illustration
how price can be swished around in an illiquid micro cap
like this by a one man band playing around with c. £30K.

antha, hubba used to say he’d put £48K in.

(mind you, hubba also used to say back in early summer
that he would stop posting after 30th june, so i suppose
one shouldn’t take what hubba says at face value? atb.)

hi dan, i doubt that earl is anything to do with align. they’re a useless
bunch of spivs with a truly dreadful track record on investment and
research imv, but they usually try to sound slightly more sophisticated
with their messaging about the companies they are trying to ramp.

it looks like earl has only partially dumped his position, as he’s still
pumping away here, on twitter & with two IDs (so far) over on advfn.

one way to earn a living i suppose, seems a bit of an effort though.

well, useful guage of the liquidity here, a few sells in a row
totalling c. £12,500 sent the share price straight back down again.